Participants also had to have at least one other underlying conditionsuch as obesity, hypertension or heart disease
INTRODUCTION The recent and rapid rise of the GLP-1 receptor agonists semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro and Zepbound) offers a critical lens through which we can examine the intersection of financialization, patent abuse, and health inequities in the pharmaceutical industry
[1] [2] Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities
These include Ozempic and Rybelsus (which both use the same active ingredient as Wegovy but are approved for diabetes treatment), Zepbound (which uses the same active ingredient as Mounjaro but is approved for weight loss), Trulicity, Victoza, and more
The average retail price could range from $1,300 to $1,500 at local pharmacies